Medicrea International SA PEG
What is the PEG of Medicrea International SA?
The PEG of Medicrea International SA is N/A
What is the definition of PEG?
Price/earnings to growth (PEG) ratio is a stock’s P/E ratio divided by a predicted growth rate of its earnings for a time period of 5 years.
= forward PE / 5-year EPS growth rate
The PEG ratio is calculated by dividing the P/E ratio by the company's expected earnings growth rate in the next 5 years. Since using just the P/E ratio would make high-growth companies appear overvalued relative to others, the PEG ratio is considered to be a convenient approximation. PEG is a widely employed indicator of a stock's possible true value.
Similar to P/E ratios, a lower PEG means that the stock is undervalued more. It is favored by many over the price/earnings ratio because it also accounts for growth. The PEG ratio of 1 is sometimes said to represent a fair trade-off between the values of cost and the values of growth, indicating that a stock is reasonably valued given the expected growth. A crude analysis suggests that companies with PEG values between 0 and 1 may provide higher returns. A PEG Ratio can also be a negative number if a stock's present income figure is negative, (negative earnings) or if future earnings are expected to drop (negative growth). PEG ratios calculated from negative present earnings are viewed with skepticism as almost meaningless, other than as an indication of high investment risk.
What does Medicrea International SA do?
Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracolumbar fixation; PASS TULIP, a top loading posterior fixation system; PASS DEGEN for thoracic and lumbar degenerative indications; PASS OCT, an occipito-cervico-thoracic fixation system; PASS MIS, a posterior anchoring system; PASS Antérieur that offers a range of specific implants enabling surgery using an anterior approach; IMPIX C, a sterile PEEK Optima cervical interbody device; IMPIX-C+, a sterile PEEK Optima cervical interbody device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK Optima cervical interbody device that is preassembled on holder/ impactor and delivers with a disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK Optima cervical interbody device, which is prefilled with synthetic bone substitutes; and GRANVIA-C, a MRI compatible ceramic cervical disc. In addition, it provides implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar interbody device for posterior approach; IMPIX-TLIF, a sterile PEEK Optima lumbar interbody device for transforaminal approach with a pre-assembled PEEK control lead; IMPIX-ALIF, a sterile PEEK Optima lumbar interbody device for anterior approach; STABOLT, an anatomically-shaped anterior plate; OSMOSYS, a macroporous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK Optima lumbar interbody devices for direct or oblique lateral approach; and X-JAWS, a titanium lumbar staple to secure a lateral or an anterior cage. Its implants are designed to treat scoliosis, degenerative diseases, malformations, trauma, and tumors; and used in various traditional and surgical procedures. The company was founded in 1990 and is headquartered in Rillieux-la-Pape, France.